Related Experiment Video

Updated: Aug 29, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

In heart failure, all beta-blockers are not necessarily equal

W H Wilson Tang1, Michael Militello, Gary S Francis

  • 1The George M. and Linda H. Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA. tangw@ccf.org

Cleveland Clinic Journal of Medicine
|December 23, 2003
PubMed

Insights

In heart failure patients, carvedilol improved survival compared to immediate-release metoprolol tartrate. This highlights that beta-blockers, like carvedilol and metoprolol succinate, have different effects and should be used at appropriate doses.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure (HF) is a complex syndrome requiring effective pharmacotherapy.
  • Beta-blockers are a cornerstone of HF treatment, but specific agents and dosing strategies vary.
  • The Carvedilol or Metoprolol European Trial (COMET) investigated comparative efficacy in HF patients.

Purpose of the Study:

  • To compare the survival benefits of carvedilol versus immediate-release metoprolol tartrate in patients with heart failure.
  • To evaluate the clinical implications of differing effects within the same drug class (beta-blockers).

Main Methods:

  • The COMET trial compared carvedilol (25 mg twice daily) with immediate-release metoprolol tartrate (50 mg twice daily) in heart failure patients.
  • Survival outcomes were the primary endpoint.

Main Results:

  • Carvedilol demonstrated superior survival benefits compared to immediate-release metoprolol tartrate in the COMET trial.
  • The study raised questions about the equivalence of target doses used for the two beta-blockers.
  • Findings underscore that not all drugs within the same class yield identical clinical outcomes.

Conclusions:

  • Carvedilol, metoprolol succinate, and bisoprolol are beneficial in managing heart failure.
  • Optimizing the use of evidence-based beta-blockers at appropriate doses is crucial for improving patient survival in heart failure.

More Related Videos

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models07:49

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models

Published on: July 21, 2023

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...